PMID- 36122520
OWN - NLM
STAT- MEDLINE
DCOM- 20221021
LR  - 20221021
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 155
DP  - 2022 Nov
TI  - Insights into stimuli-responsive diselenide bonds utilized in drug delivery 
      systems for cancer therapy.
PG  - 113707
LID - S0753-3322(22)01096-4 [pii]
LID - 10.1016/j.biopha.2022.113707 [doi]
AB  - Due to the complexity and particularity of cancer cell microenvironments, redox 
      responsive drug delivery systems (DDSs) for cancer therapy have been extensively 
      explored. Compared with widely reported cancer treatment systems based on 
      disulfide bonds, diselenide bonds have better redox properties and greater 
      anticancer efficiency. In this review, the significance and application of 
      diselenide bonds in DDSs are summarized, and the stimulation sensitivity of 
      diselenide bonds is comprehensively reported. The potential and prospects for the 
      application of diselenide bonds in next-generation anticancer drug treatment 
      systems are extensively discussed.
CI  - Copyright (c) 2022 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Shi, Zhenfeng
AU  - Shi Z
AD  - Department of Urology Surgery Center, The People's Hospital of Xinjiang Uyghur 
      Autonomous Region, Urumqi 830002, PR China. Electronic address: 
      zhenfengshi@163.com.
FAU - Liu, Jifang
AU  - Liu J
AD  - Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an 710021, PR 
      China; College of Life Science, Northwest University, Xi'an 710069, PR China. 
      Electronic address: liujifang553@163.com.
FAU - Tian, Lei
AU  - Tian L
AD  - Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an 710021, PR 
      China; College of Bioresources Chemical and Materials Engineering, Shaanxi 
      University of Science & Technology, Xi'an 710021, PR China. Electronic address: 
      leitian115@gmail.com.
FAU - Li, Jingyi
AU  - Li J
AD  - Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an 710021, PR 
      China. Electronic address: lijingyimmc@aliyun.com.
FAU - Gao, Yue
AU  - Gao Y
AD  - Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an 710021, PR 
      China. Electronic address: 201904030101@sust.edu.cn.
FAU - Xing, Yue
AU  - Xing Y
AD  - Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an 710021, PR 
      China. Electronic address: yuexingyx@126.com.
FAU - Yan, Wenjing
AU  - Yan W
AD  - Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an 710021, PR 
      China. Electronic address: WenjingYan1@outlook.com.
FAU - Hua, Chenyu
AU  - Hua C
AD  - Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an 710021, PR 
      China. Electronic address: chenyuhua200112@163.com.
FAU - Xie, Xiaolin
AU  - Xie X
AD  - Shaanxi Panlong Pharmaceutical Group Co., Ltd. Xi'an 710025, PR China. Electronic 
      address: 1970wujie@163.com.
FAU - Liu, Chang
AU  - Liu C
AD  - Zhuhai Jinan Selenium Source Nanotechnology Co., Ltd., Zhuhai 519030, PR China. 
      Electronic address: sesource_liuchang@163.com.
FAU - Liang, Chengyuan
AU  - Liang C
AD  - Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an 710021, PR 
      China. Electronic address: chengyuanliang@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220916
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Disulfides)
RN  - 0 (Drug Carriers)
SB  - IM
MH  - Humans
MH  - *Antineoplastic Agents/therapeutic use
MH  - Oxidation-Reduction
MH  - *Neoplasms/drug therapy
MH  - Drug Delivery Systems
MH  - Disulfides
MH  - Drug Carriers/chemistry
MH  - Tumor Microenvironment
OTO - NOTNLM
OT  - Anticancer drugs
OT  - Diselenide bonds
OT  - Drug delivery systems (DDSs)
OT  - Reactive oxygen species (ROS)
OT  - Redox responsiveness
OT  - Reduced glutathione (GSH)
COIS- Conflict of interest statement The authors declare no conflict of interest.
EDAT- 2022/09/20 06:00
MHDA- 2022/10/22 06:00
CRDT- 2022/09/19 18:21
PHST- 2022/07/27 00:00 [received]
PHST- 2022/09/08 00:00 [revised]
PHST- 2022/09/13 00:00 [accepted]
PHST- 2022/09/20 06:00 [pubmed]
PHST- 2022/10/22 06:00 [medline]
PHST- 2022/09/19 18:21 [entrez]
AID - S0753-3322(22)01096-4 [pii]
AID - 10.1016/j.biopha.2022.113707 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2022 Nov;155:113707. doi: 10.1016/j.biopha.2022.113707. Epub 
      2022 Sep 16.